STEVENSON, Md., Dec. 28, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Credit Suisse Group AG (NYSE:CS) (“Credit Suisse” or the “Company”) American Depositary Receipts (“ADRs”) during the period between March 20, 2015 and February 3, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until February 20, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Credit Suisse securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company consistently failed to comply with its own risk protocols and control systems governing its investment operations and acquired risky, highly illiquid securities valued in the billions of dollars.
According to the complaint, following a February 4, 2016 announcement of the its fourth quarter and full year 2015 results, which included $632 million in write-downs attributable to the sales of illiquid securities, the value of Credit Suisse ADRs declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Credit Suisse securities purchased on or after March 20, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


How Marco Pharma International Preserves German Homeopathic Traditions in America
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
FTC Questions Apple News Over Alleged Bias Against Conservative Media 



